Increasing Awareness and Understanding of Amyloid Transthyretin Cardiomyopathy (ATTR-CM)

From Pfizer, Inc.

The funder's mission is to improve outcomes for patients with advanced prostate cancer and to advance research, innovation, clinical expertise, and education for healthcare professionals in Latin America.

Type of Support

Overview

This grant program focuses on encouraging organizations to propose educational activities aimed at healthcare professionals. The goal is to improve the identification, suspicion, diagnosis, and treatment of heart failure patients at risk for Transthyretin (TTR) Amyloidosis. It emphasizes the need for increased awareness among healthcare professionals to recognize heart failure patients who might be at risk for TTR Amyloidosis and advocates for an evidence-based approach to facilitate early and appropriate patient identification.

Eligibility

Organization's Location
USA
Program Location
USA
Organization Type
up to 100k

Submission

Visit Apply for more information.

Similar grants